Cosmos Health Inc. is a diversified, vertically integrated global healthcare company. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life, Mediterranation, bio-bebe, C-Sept and C-Scrub. Through its subsidiary Cana Laboratories S.A., it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. It also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and over-the-counter (OTC) medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the United Kingdom. It also has research and development (R&D) partnerships targeting health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of patented nutraceuticals, specialized root extracts, proprietary complex generics, and OTC products.

Employees

Sector

Pharmaceuticals

More about the company

Income Statement and Estimates

More financial data

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Delayed OTC Markets Other stock markets 11:14:35 2021-10-05 EDT			5-day change	1st Jan Change
4.510 ^USD	-5.65%		-2.45%	-

11:43am	Cosmos Health Introduces Four 18 Series Products with Projected Annualized Revenue and Gross Profit in the United States	CI
06-12	Cosmos Health Gets New Contract Manufacturing Orders for 253,657 Units Across Multiple Medicines	MT

Market Cap	11.41M 9.84M 9.05M 8.49M 15.95M 1.08B 16.11M 107M 41.8M 528M 42.83M 41.92M 1.83B	P/E Ratio 2026 *	21x	P/E Ratio 2027 *	3x
Enterprise Value	11.41M 9.84M 9.05M 8.49M 15.95M 1.08B 16.11M 107M 41.8M 528M 42.83M 41.92M 1.83B	EV / Sales 2026 *	0.13x	EV / Sales 2027 *	0.1x
Free-Float	67.73%	Yield 2026 *	-	Yield 2027 *	-

11:43am	Cosmos Health Introduces Four 18 Series Products with Projected Annualized Revenue and Gross Profit in the United States	CI
06-12	Cosmos Health Gets New Contract Manufacturing Orders for 253,657 Units Across Multiple Medicines	MT
06-11	Cosmos Health Signs Letter of Intent to Buy Doc Pharma	MT
06-10	Cosmos Health Unit Signs 3-Year Manufacturing Deal With Verisfield	MT
06-08	Cosmos Health Unit Acquires Patent Application From Cloudpharm	MT
06-05	Cosmos Health Inc. Announces U.S. Launch of Oliv18 Targeting Cardiovascular and Antioxidant Categories	CI
06-01	Cosmos Health Inc. Enters USD 69 Billion Global Animal Health Industry With Veterinary C-Scrub Wash 4% Following Successful European Standard Testing Under EN 1656 And EN 1657	CI
05-26	Cosmos Health targets $200 mln revenue, $44 mln adjusted EBITDA by 2029	RE
05-26	Cosmos Health Inc. Provides Earnings Guidance for the Year 2026, 2027, 2028 and 2029	CI
05-20	Cosmos Health Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-20	Cosmos Health Completes Phase 1 Execution of Liv18 Ahead of Schedule	MT
04-17	Cosmos Health to Launch Cur18 Curcumin Supplement in US in Q2	MT
04-15	Cosmos Health Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI

09:04am	Cosmos Health Provides Update on United States Portfolio; Four 18 Series Products Introduced With Projected Annualized Revenue Over $22.7M and Approximately $17.0M Gross Profit	GL
09:01am	Cosmos Health Provides Update on United States Portfolio; Four 18 Series Products Introduced With Projected Annualized Revenue Over $22.7M and Approximately $17.0M Gross Profit	AQ
06-12	Cosmos Health Receives New Contract Manufacturing Orders Totaling 253,657 Units Across a Range of Medicines	GL
06-12	Cosmos Health Reports Annualized Sales Exceeding $1.5M for Its C-Scrub and C-Sept Antiseptic Brands in the UK and Greece; Plans EU Expansion Targeting $7.4M in Revenue and $5.3M in Gross Profit	GL
06-11	Cosmos Health Signs LOI to Acquire Doc Pharma S.A., a European GMP Pharmaceutical Manufacturer, a Transformative Step Expected to Boost Assets, Profitability, Production Capacity, and Product Portfolio	GL

Cosmos Holdings Inc. Stock OTC Markets

Stocks

COSM

US2214131078

Pharmaceuticals

Valuation: Cosmos Holdings Inc.

Latest news : Cosmos Holdings Inc.

Press Releases: Cosmos Holdings Inc.

News in other languages: Cosmos Holdings Inc.

Quotes and Performance

Managers and Directors: Cosmos Holdings Inc.

Pharmaceuticals Wholesale

Financials

Company Profile

Income Statement and Estimates

Quarterly revenue - Rate of surprise

24-11-29	Dalla farmaceutica al fitness: la corsa all'oro del bitcoin - Crypt On It
24-11-28	De la farmacia al gimnasio: la fiebre del bitcoin - Crypto Recap
22-12-05	Pelè non è in cure palliative - figlia
22-12-01	BASF : lance un agent nacrant naturel à base de cire

Manager	Title	Age	Since
Grigorios Siokas CEO	Chief Executive Officer	60	2016-02-25
George Terzis DFI	Director of Finance/CFO	44	2020-11-10
Nikolaos Bardakis COO	Chief Operating Officer	-	2023-01-31

Director	Title	Age	Since
Demetrios Demetriades BRD	Director/Board Member	59	2014-01-12
Grigorios Siokas CHM	Chairman	60	2016-02-25
John Hoidas BRD	Director/Board Member	60	2016-11-17

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
COSMOS HOLDINGS INC.	-5.65%	-2.45%	-	-	11.41M
MCKESSON CORPORATION	+0.81%	+1.78%	+8.43%	+95.03%	91.79B
CARDINAL HEALTH, INC.	+0.54%	+10.60%	+39.25%	+153.66%	52.43B
SIGMA HEALTHCARE LIMITED	+6.06%	-4.11%	-13.85%	+229.41%	21.42B
SHANGHAI PHARMACEUTICALS HOLDING CO., LTD	-0.37%	+0.12%	-11.28%	-26.90%	8.13B
HUADONG MEDICINE CO., LTD	-0.38%	+2.04%	-34.90%	-30.42%	7.54B
SINOPHARM GROUP CO. LTD.	-0.41%	-1.63%	-11.82%	-36.59%	6.77B
H. LUNDBECK A/S	-1.05%	-3.48%	+10.31%	+18.86%	6.49B
GALENICA AG	-1.00%	0.00%	-1.92%	+18.04%	5.32B
JOINTOWN PHARMACEUTICAL GROUP CO., LTD	+1.67%	-2.01%	-10.48%	-14.79%	3.53B
Average	+0.04%	+0.88%	-2.92%	+45.14%	22.6B
Weighted average by Cap.	+1.07%	+1.98%	+10.42%	+104.03%

	2026 *	2027 *
Net sales	87.3M 75.24M 69.25M 64.96M 122M 8.25B 123M 819M 320M 4.04B 328M 321M 13.98B	111M 95.5M 87.89M 82.45M 155M 10.47B 156M 1.04B 406M 5.13B 416M 407M 17.74B
Net income	-	-
Net Debt	-	-